Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
stocks
Overvalued ASX share hurt by normalising conditions
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.40 | 52.50 | 0.58% |
| CAC 40 | 8,073.79 | 123.61 | 1.55% |
| DAX 40 | 23,979.96 | 410.00 | 1.74% |
| Dow JONES (US) | 47,021.95 | 34.85 | 0.07% |
| FTSE 100 | 9,788.63 | 106.06 | 1.10% |
| HKSE | 26,649.06 | 407.23 | 1.55% |
| NASDAQ | 23,335.51 | 330.97 | 1.44% |
| Nikkei 225 | 50,911.76 | 635.39 | 1.26% |
| NZX 50 Index | 13,617.48 | 18.27 | 0.13% |
| S&P 500 | 6,783.48 | 54.68 | 0.81% |
| S&P/ASX 200 | 8,835.90 | 44.10 | 0.50% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |